FP 02.2

Drug Profile

FP 02.2

Alternative Names: FP 02; FP-02-2; FP02.2; Hepsyn-B™; HepTcell

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator Immune Targeting Systems
  • Developer Altimmune
  • Class Hepatitis B vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 01 Sep 2015 Vaxin is now called Altimmune
  • 21 Jul 2015 Vaxin receives a Notice of Allowance from USPTO for Hepatitis B virus infection in US
  • 01 Jul 2015 Phase-I clinical trials in Hepatitis B (Adjunctive treatment) in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top